Krebsbekämpfung mit Glycogenesys - 500 Beiträge pro Seite

[steffen712000]

Glycogenesys [GLGS | Nasdaq]

http://www.steffen-vogler.i-networx.de/

alles zur Aktie, zur company und eigene Recherchen!

GCS-100, die drug, die unter den 100 vielversprechendsten Medikamenten gehandelt wird!

viel spass beim stöpern und studieren

s.

[sf_mod]

Moin,

bin seit einigen Wochen in die Aktie investiert (via US-Order bei meiner Bank). Sehe vielversprechendes Potential in dem Unternehmen. Allerdings ist die Abhängigkeit von GCS-100 extrem groß, so daß bei schlechten News die Aktie gewaltig abstürzen wird. Auf der anderen Seite ist die Phantasie auf ein Partnering oder eine Übernahme durch einen Big Pharma / Big Biotech (z.B. Amgen) da. Es bleibt also interessant, und ich überlege, ob ich nicht noch verbilligen soll bei derzeitigen Kursen.

Gruß

SF_MOD

[flecky1]

Hi Ihr!!!

Habe vor von Glycogenesys einige Stücke zu kaufen und bin guter Hoffnung, daß die Tests gut verlaufen werden.
Wenn diese Sache klappt und das Medikament die Zulassung bekommen sollte, womit ich natürlich rechne, dann möchte ich auch dabei sein.

Natürlich muß Glyco dafür noch Hürden meistern, welche
ziemlich hoch gesteckt sind.

Ich hoffe wie alle das dies alles gut verläuft. Es heißt ja auch:

Besser man wagt alles
und nimmt einen Teil
der bösen Folgen auf sich,
als das man alles ängstliche erwägt,
damit man nie böse Folgen zu tragen hat.
Wer sich zur Tat erschließt,
dem gehört meist auch der Sieg.

Viel Glück!!!

[muhsin]

morgen,

hat jemeand hier n´Ahnung warum der Kurs von GLGS so abgesagt ist?

Grüße und schönen Sonntag

[muhsin]

http://finance.lycos.com/livechartsplus/spawn.asp?url=http%3…
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



FORM 8-K



CURRENT REPORT



Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of earliest event reported): June 4, 2004




GLYCOGENESYS, INC.

(Exact name of registrant as specified in charter)




NEVADA 0-26476 33-0231238
(State or Other Jurisdiction

of Incorporation)
(Commission

File Number)
(IRS Employer

Identification No.)





31 St. James Avenue, Boston, Massachusetts 02116
(Address of principal executive officers) (Zip Code)



Registrant’s telephone number, including area code: [phone]



Not Applicable

(Former name or former address, if changed since last report)




--------------------------------------------------------------------------------





--------------------------------------------------------------------------------

ITEM 5. OTHER ITEMS



On June 4, 2004, GlycoGenesys, Inc. (the “Company”) held a public conference call in which Bradley Carver, the Company’s Chief Executive Officer and President, discussed the Company’s current clinical trial plans, among other things. An excerpt of the portions of Mr. Carver’s script discussing the Company’s clinical trial plans is set forth in Exhibit 99.1 hereto which is incorporated herein by reference.



Forward-looking statements are made throughout Exhibit 99.1. Typically, the use of the words “believe”, “anticipate”, “plan”, “expect”, “seek”, “estimate” and similar expressions identify forward-looking statements. Unless a passage describes a historical event, the statement should be considered a forward-looking statement. In keeping with the “Safe Harbor” provision of the Private Securities Litigation Reform Act of 1995, it should be noted that forward-looking statements regarding the Company’s future expectations and projections are not guarantees of future performance. They involve risks, uncertainties and assumptions, and many of the factors that will determine the Company’s future results are beyond the Company’s ability to control or predict. Therefore, actual results may differ significantly from those suggested by forward-looking statements. These risks include the inability to obtain additional funding, the failure to successfully bring GCS-100 to market, the failure to protect or maintain rights to intellectual property, delisting from Nasdaq, the introduction of competing drugs as well as those risks detailed under the heading “Certain Factors That May Affect Future Results” contained in Item 3 of the Company’s Quarterly Report of Form 10-Q for the quarter ended March 31, 2004.



Exhibit 99.1 is dated as of the date hereof and reflects management’s views as of such date. The Company undertakes no obligation to update the information contained in Exhibit 99.1, including forward-looking statements, to reflect subsequently occurring events or circumstances. This report will not be deemed an admission as to the materiality of any information in
the report that is required to be disclosed solely by Regulation FD.



ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS



The following exhibits are filed as part of this Form 8-K.





Exhibit Number

--------------------------------------------------------------------------------
Description

--------------------------------------------------------------------------------


99.1 Partial Script from June 4, 2004 Conference Call





SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Dated: June 4, 2004


By: /s/ Bradley J. Carver

--------------------------------------------------------------------------------

Bradley J. Carver

President and Chief Executive Officer




--------------------------------------------------------------------------------

Exhibit 99.1



In the first quarter, we continued our research efforts at Dana Farber under the direction of Dr. Ken Anderson, who was the PI for MLNM’s Velcade. We are quite pleased with Ken’s research on GCS-100 to date. Based on current data and recent conversations with Dr. Anderson and Dr. Richardson, we are working toward initiating clinical trials in multiple myeloma later this year at Dana Farber.



Two of our scientific and medical colleagues and I will travel to London next week to meet with Dr. Finbarr Cotter to meet some of his colleagues to discuss possible clinical trials in other blood borne cancers. These discussions are brought about due to the encouraging preclinical data Dr. Cotter generated on GCS-100 over the past year.



Looking ahead at our clinical trial program, first we initiated the phase I trial to enroll patients with solid tumors to determine the maximum dose that can be given in Phase II trials.



We’re currently planning a clinical trial to begin later in 2004 that will enroll multiple myeloma patients. As I mentioned earlier, we expect this trial to be conducted at Dana Farber with Dr. Ken Anderson and his colleagues.



We plan to request Fast Track designation by early 2005.



In the first or second quarter of 2005, we also plan to begin a phase II trial in a solid tumor indication.



The indication will be based on results from the current phase I trial, previous clinical trials and additional research conducted during the remainder of 2004.



Assuming positive data from the multiple myeloma trial, we plan to initiate pivotal clinical trials for multiple myeloma in 2005.



Our target is to begin filing the NDA in late 2006 from the multiple myeloma pivotal trials for possible approval in late 2007.





--------------------------------------------------------------------------------
End of Filing